Palliative care research on psychedelic interventions is promising, with Dr. Roland Griffiths’ work on psilocybin showing benefits. Studies have shown improvements in mood, quality of life, and anxiety in cancer patients. Research also indicates positive effects on physical, psychological, and existential outcomes with psychedelics. Challenges include access to professional training. Ketamine is already used for palliative care in Brazil, highlighting the need for more research in the field. Griffiths’ own experience with cancer underscored the potential for psychedelic therapies in end-of-life care. The approach requires a shift in how professionals interact with patients, focusing on deep involvement and connection.
Source link
How Psychedelic Drugs Can Aid Patients at the End of Life
